Literature DB >> 16707164

Adrenal cortical responses to low- and high-dose ACTH(1-24) administration in major depressives vs. matched controls.

Robert T Rubin1, Thomas H Miller, Michael E Rhodes, R Kenneth Czambel.   

Abstract

Increased hypothalamo-pituitary-adrenocortical (HPA) axis activity occurs in 30-50% of patients with major depression. This includes normal-to-increased adrenal cortical hormone (cortisol) secretion in spite of reduced corticotropin (ACTH) stimulation. A possible explanation is increased adrenal responsiveness to ACTH. Supporting this possibility is the finding of increased adrenal volume, which reverts to normal with successful treatment. Eight female and six male patients with major depression, and eight female and six male individually matched controls, underwent two test sessions 5-7 days apart. On the first day, a low ACTH(1-24) dose (0.014 microg/kg i.v.), equivalent to 1 microg in a 70-kg individual, was given. On the second day, a supramaximal stimulating dose (250 microg i.v.) was given. Serial blood samples were analyzed for immunoreactive (IR-)ACTH, ACTH(1-39), and cortisol. There were no significant sex or patient-control differences in IR-ACTH areas under the curve (AUCs) following low-dose ACTH(1-24), and the correlation between patient and matched control AUCs was +0.71, indicating good correspondence in the amount of circulating ACTH(1-24) available for adrenal stimulation. There were no significant sex or patient-control differences in cortisol response and no significant interaction between dose and subject group, indicating that patients did not differ from controls in their cortisol responses to either low- or high-dose ACTH(1-24). These findings do not indicate increased adrenal cortical responsiveness in patients with major depression. Neurochemical/neurohormonal and neural stimulatory factors other than ACTH might be responsible for the increased adrenal gland size and cortisol secretion, in spite of reduced pituitary ACTH secretion, that has been reported in this illness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707164     DOI: 10.1016/j.psychres.2005.10.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

Review 1.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

2.  Vesicular Glutamate Transporter 1 Knockdown in Infralimbic Prefrontal Cortex Augments Neuroendocrine Responses to Chronic Stress in Male Rats.

Authors:  Brent Myers; Jessica M McKlveen; Rachel Morano; Yvonne M Ulrich-Lai; Matia B Solomon; Steven P Wilson; James P Herman
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

3.  Mapping of hormones and cortisol responses in patients after Lyme neuroborreliosis.

Authors:  Ivar Tjernberg; Martin Carlsson; Jan Ernerudh; Ingvar Eliasson; Pia Forsberg
Journal:  BMC Infect Dis       Date:  2010-02-05       Impact factor: 3.090

4.  Cortisol and Dehydroepiandrosterone Response to Adrenocorticotropic Hormone and Frailty in Older Women.

Authors:  Nina P Le; Ravi Varadhan; Linda P Fried; Anne R Cappola
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-04-30       Impact factor: 6.053

Review 5.  Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder.

Authors:  JiaJun Liu; Femke Buisman-Pijlman; Mark R Hutchinson
Journal:  Front Neurosci       Date:  2014-09-30       Impact factor: 4.677

6.  The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Sibylle Häfner; Christoph Born; Sascha Herrmann; Rainer Rupprecht
Journal:  PLoS One       Date:  2009-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.